Deutsche Bank AG Raises Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

Deutsche Bank AG raised its holdings in Biohaven Ltd. (NYSE:BHVN - Free Report) by 25.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 169,773 shares of the company's stock after purchasing an additional 33,987 shares during the quarter. Deutsche Bank AG owned 0.17% of Biohaven worth $6,341,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. HighTower Advisors LLC raised its position in Biohaven by 6.1% in the fourth quarter. HighTower Advisors LLC now owns 5,870 shares of the company's stock valued at $219,000 after purchasing an additional 335 shares during the period. FSC Wealth Advisors LLC raised its position in Biohaven by 3.3% in the fourth quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company's stock valued at $579,000 after purchasing an additional 500 shares during the period. Prudential Financial Inc. raised its position in Biohaven by 9.4% in the fourth quarter. Prudential Financial Inc. now owns 5,980 shares of the company's stock valued at $223,000 after purchasing an additional 514 shares during the period. Amalgamated Bank raised its position in Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company's stock valued at $109,000 after purchasing an additional 527 shares during the period. Finally, DnB Asset Management AS raised its holdings in shares of Biohaven by 8.2% in the 4th quarter. DnB Asset Management AS now owns 7,526 shares of the company's stock valued at $281,000 after buying an additional 571 shares during the period. Hedge funds and other institutional investors own 88.78% of the company's stock.

Biohaven Price Performance

Shares of Biohaven stock traded up $0.24 on Friday, reaching $15.67. 2,283,708 shares of the company were exchanged, compared to its average volume of 1,238,778. Biohaven Ltd. has a 1-year low of $14.69 and a 1-year high of $55.70. The company has a market cap of $1.60 billion, a P/E ratio of -1.68 and a beta of 1.18. The stock's 50 day moving average price is $20.97 and its 200-day moving average price is $33.11.

Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($2.17) EPS for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.50). On average, research analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on BHVN shares. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a "buy" rating in a report on Thursday, March 20th. Morgan Stanley dropped their target price on Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. JPMorgan Chase & Co. dropped their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Royal Bank of Canada downgraded Biohaven from an "outperform" rating to a "sector perform" rating and dropped their target price for the company from $54.00 to $21.00 in a research report on Monday. Finally, Cantor Fitzgerald raised Biohaven to a "strong-buy" rating in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $59.46.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs purchased 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This trade represents a 1.43% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.00% of the stock is currently owned by corporate insiders.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.